<DOC>
	<DOCNO>NCT02302274</DOCNO>
	<brief_summary>The study aim use flecainide infusion test diagnostic test unmask conceal Brugada Syndrome case . It propose assess safety profile test US patient high sensitivity compare procainamide infusion ( conventional drug use USA ) . As substudy propose apply test early ARVC case order evaluate ECG change similar see Brugada Syndrome could unmask flecainide iv .</brief_summary>
	<brief_title>Diagnostic Value Safety Flecainide Infusion Test Brugada Syndrome</brief_title>
	<detailed_description>Brugada Syndrome inherit arrhythmogenic disease responsible life-threatening arrhythmia sudden cardiac death young individual structural normal heart . It characterize peculiar ECG pattern , pattern could intermittent . The infusion sodium channel blocker ( flecainide , ajmaline , procainamide ) use unmask conceal ECG pattern , thus provide essential contribution diagnosis condition . In current clinical practice USA , procainamide use diagnostic purpose ; however Europe ajmaline flecainide , available iv formulation , widely use . European Japanese study demonstrate use flecainide harbor less risks adverse event patient may higher accuracy unravel presence disease . In present study investigator propose use flecainide infusion test Cardiovascular Genetics Program NYUMC , order ass sensitivity specificity diagnose disease compare incidence adverse event observe procainamide use . Additionally , investigator propose extend study protocol patient suspect diagnosis Arrhythmogenic Right Ventricular Tachycardia ( ARVC ) , due possible overlap two condition . The study follow aim : 1 . To demonstrate high sensitivity specificity flecainide iv infusion compare procainamide infusion diagnosis Brugada Syndrome . 2 . To demonstrate flecainide equally safe safer procainamide use diagnose Brugada Syndrome . 3 . To demonstrate flecainide high sensitivity specificity diagnose also patient early stage Arrhythmogenic Right Ventricular Cardiomyopathy ( ARVC ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Brugada Syndrome</mesh_term>
	<mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>Suspect diagnosis Brugada Syndrome ARVC Idiopathic ventricular fibrillation suspect conceal Brugada syndrome Family history Brugada Syndrome Family history unexpected cardiac sudden death Type 1 Brugada Syndrome ECG Pregnancy History and/or evidence ischemic cardiomyopathy Recent myocardial infarction Allergy know adverse reaction flecainide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Brugada Syndrome</keyword>
	<keyword>ARVC</keyword>
	<keyword>flecainide</keyword>
	<keyword>ST elevation</keyword>
</DOC>